Cargando…

Procalcitonin Predicts Response to Beta-Lactam Treatment in Hospitalized Children with Community-Acquired Pneumonia

BACKGROUND: Antibiotic treatment of community-acquired pneumonia (CAP) in children remains mostly empirical because clinical and paraclinical findings poorly discriminate the principal causes of CAP. Fast response to beta-lactam treatment can be considered a proxy of pneumococcal aetiology. We aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Jérémie F., Leis, Alexander, Lecarpentier, Thibault, Raymond, Josette, Gendrel, Dominique, Chalumeau, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3355171/
https://www.ncbi.nlm.nih.gov/pubmed/22615848
http://dx.doi.org/10.1371/journal.pone.0036927
_version_ 1782233342959157248
author Cohen, Jérémie F.
Leis, Alexander
Lecarpentier, Thibault
Raymond, Josette
Gendrel, Dominique
Chalumeau, Martin
author_facet Cohen, Jérémie F.
Leis, Alexander
Lecarpentier, Thibault
Raymond, Josette
Gendrel, Dominique
Chalumeau, Martin
author_sort Cohen, Jérémie F.
collection PubMed
description BACKGROUND: Antibiotic treatment of community-acquired pneumonia (CAP) in children remains mostly empirical because clinical and paraclinical findings poorly discriminate the principal causes of CAP. Fast response to beta-lactam treatment can be considered a proxy of pneumococcal aetiology. We aimed to identify the best biological predictor of response to beta-lactam therapy in children hospitalized for CAP. METHODS: A retrospective, single-centre cohort study included all consecutive patients 1 month to 16 years old hospitalized in a teaching hospital in Paris, France, because of CAP empirically treated with a beta-lactam alone from 2003 to 2010. Uni- and multivariate analyses were used to study the ability of routine biological parameters available in the Emergency Department to predict a favourable response to beta-lactam (defined as apyrexia within 48 hours of treatment onset). RESULTS: Among the 125 included patients, 85% (106) showed a favourable response to beta-lactam. In multivariate logistic regression, we found procalcitonin (PCT) the only independent predictor of apyrexia (p = 0.008). The adjusted odds ratio for the decadic logarithm of PCT was 4.3 (95% CI 1.5–12.7). At ≥3 ng/mL, PCT had 55.7% sensitivity (45.7–65.3), 78.9% specificity (54.4–93.9), 93.7% positive predictive value (84.5–98.2), 24.2% negative predictive value (14.2–36.7), 2.64 positive likelihood ratio (1.09–6.42) and 0.56 negative likelihood ratio (0.41–0.77). In the 4 children with a PCT level ≥3 ng/mL and who showed no response to beta-lactam treatment, secondary pleural effusion had developed in 3, and viral co-infection was documented in 1. CONCLUSIONS: PCT is the best independent biologic predictor of favourable response to beta-lactam therapy in children hospitalized for CAP. Thus, a high PCT level is highly suggestive of pneumococcal aetiology. However, a 3-ng/mL cut-off does not seem compatible with daily medical practice, and additional research is needed to further define the role of PCT in managing CAP in children.
format Online
Article
Text
id pubmed-3355171
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-33551712012-05-21 Procalcitonin Predicts Response to Beta-Lactam Treatment in Hospitalized Children with Community-Acquired Pneumonia Cohen, Jérémie F. Leis, Alexander Lecarpentier, Thibault Raymond, Josette Gendrel, Dominique Chalumeau, Martin PLoS One Research Article BACKGROUND: Antibiotic treatment of community-acquired pneumonia (CAP) in children remains mostly empirical because clinical and paraclinical findings poorly discriminate the principal causes of CAP. Fast response to beta-lactam treatment can be considered a proxy of pneumococcal aetiology. We aimed to identify the best biological predictor of response to beta-lactam therapy in children hospitalized for CAP. METHODS: A retrospective, single-centre cohort study included all consecutive patients 1 month to 16 years old hospitalized in a teaching hospital in Paris, France, because of CAP empirically treated with a beta-lactam alone from 2003 to 2010. Uni- and multivariate analyses were used to study the ability of routine biological parameters available in the Emergency Department to predict a favourable response to beta-lactam (defined as apyrexia within 48 hours of treatment onset). RESULTS: Among the 125 included patients, 85% (106) showed a favourable response to beta-lactam. In multivariate logistic regression, we found procalcitonin (PCT) the only independent predictor of apyrexia (p = 0.008). The adjusted odds ratio for the decadic logarithm of PCT was 4.3 (95% CI 1.5–12.7). At ≥3 ng/mL, PCT had 55.7% sensitivity (45.7–65.3), 78.9% specificity (54.4–93.9), 93.7% positive predictive value (84.5–98.2), 24.2% negative predictive value (14.2–36.7), 2.64 positive likelihood ratio (1.09–6.42) and 0.56 negative likelihood ratio (0.41–0.77). In the 4 children with a PCT level ≥3 ng/mL and who showed no response to beta-lactam treatment, secondary pleural effusion had developed in 3, and viral co-infection was documented in 1. CONCLUSIONS: PCT is the best independent biologic predictor of favourable response to beta-lactam therapy in children hospitalized for CAP. Thus, a high PCT level is highly suggestive of pneumococcal aetiology. However, a 3-ng/mL cut-off does not seem compatible with daily medical practice, and additional research is needed to further define the role of PCT in managing CAP in children. Public Library of Science 2012-05-17 /pmc/articles/PMC3355171/ /pubmed/22615848 http://dx.doi.org/10.1371/journal.pone.0036927 Text en Cohen et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Cohen, Jérémie F.
Leis, Alexander
Lecarpentier, Thibault
Raymond, Josette
Gendrel, Dominique
Chalumeau, Martin
Procalcitonin Predicts Response to Beta-Lactam Treatment in Hospitalized Children with Community-Acquired Pneumonia
title Procalcitonin Predicts Response to Beta-Lactam Treatment in Hospitalized Children with Community-Acquired Pneumonia
title_full Procalcitonin Predicts Response to Beta-Lactam Treatment in Hospitalized Children with Community-Acquired Pneumonia
title_fullStr Procalcitonin Predicts Response to Beta-Lactam Treatment in Hospitalized Children with Community-Acquired Pneumonia
title_full_unstemmed Procalcitonin Predicts Response to Beta-Lactam Treatment in Hospitalized Children with Community-Acquired Pneumonia
title_short Procalcitonin Predicts Response to Beta-Lactam Treatment in Hospitalized Children with Community-Acquired Pneumonia
title_sort procalcitonin predicts response to beta-lactam treatment in hospitalized children with community-acquired pneumonia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3355171/
https://www.ncbi.nlm.nih.gov/pubmed/22615848
http://dx.doi.org/10.1371/journal.pone.0036927
work_keys_str_mv AT cohenjeremief procalcitoninpredictsresponsetobetalactamtreatmentinhospitalizedchildrenwithcommunityacquiredpneumonia
AT leisalexander procalcitoninpredictsresponsetobetalactamtreatmentinhospitalizedchildrenwithcommunityacquiredpneumonia
AT lecarpentierthibault procalcitoninpredictsresponsetobetalactamtreatmentinhospitalizedchildrenwithcommunityacquiredpneumonia
AT raymondjosette procalcitoninpredictsresponsetobetalactamtreatmentinhospitalizedchildrenwithcommunityacquiredpneumonia
AT gendreldominique procalcitoninpredictsresponsetobetalactamtreatmentinhospitalizedchildrenwithcommunityacquiredpneumonia
AT chalumeaumartin procalcitoninpredictsresponsetobetalactamtreatmentinhospitalizedchildrenwithcommunityacquiredpneumonia